Estrogen receptor-α-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant

Cancer Biology and Therapy

Volumn 9, Issue 5, 2010, Pages 389-396

  Long, Xinghua ^a,b,c   Fan, Meiyun ^d   Nephew, Kenneth P ^a,e,f  

^a Indiana University School of Medicine   (United States)

^b JIANGNAN UNIVERSITY   (China)

^c WUHAN UNIVERSITY   (China)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiestrogen; Breast cancer; Cytokeratin; Estrogen receptor; Fulvestrant; Tamoxifen

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

BREAST NEOPLASMS; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; KERATINS; OLIGONUCLEOTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 77953706542     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.5.10926     Document Type: Article

References (43)

1. Howell A. Faslodex. An oestrogen receptor downregulator. Eur J Cancer 2000; 36:87-8.
2. McDonnell DP. The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer. Clin Cancer Res 2005; 11:871-7.
3. Wakeling AE, Bowler J. Steroidal pure antioestrogens. J Endocrinol 1987; 112:7-10.
4. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Nat Acad Sci USA 1990; 87:6883-7.
5. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Nat Acad Sci USA 1992; 89:4037-41.
6. Wakeling AE, Bowler J. ICI 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 1992; 43:173-7.
7. Wittmann BM, Sherk A, McDonnell DP. Definition of functionally important mechanistic differences among selective estrogen receptor downregulators. Cancer Res 2007; 67:9549-60.
8. Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function and clinical use. J Clin Oncol 2000; 18:3172-86.
9. Hayes DF. Tamoxifen: Dr. Jekyll and Mr. Hyde? J Nat Cancer Inst 2004; 96:895-7.
10. Pike AC, Brzozowski AM, Walton J, Hubbard RE, Thorsell AG, Li YL, et al. Structural insights into the mode of action of a pure antiestrogen. Structure 2001; 9:145-53.
11. Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, et al. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 2005; 18:413-24.
12. Long X, Nephew KP. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J Biol Chem 2006; 281:9607-15.
13. Fan M, Bigsby RM, Nephew KP. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-alpha and essential for the antiproliferative activity of ICI 182,780 in ERalpha-positive breast cancer cells. Mol Endocrinol 2003; 17:356-65.
14. Coutts AS, Davie JR, Dotzlaw H, Murphy LC. Estrogen regulation of nuclear matrix-intermediate filament proteins in human breast cancer cells. J Cellular Biochem 1996; 63:174-84.
15. Lupien M, Jeyakumar M, Hebert E, Hilmi K, Cotnoir- White D, Loch C, et al. Raloxifene and ICI182,780 increase estrogen receptor-alpha association with a nuclear compartment via overlapping sets of hydrophobic amino acids in activation function 2 helix 12. Mol Endocrinol 2007; 21:797-816.
16. Montano MM, Ekena K, Krueger KD, Keller AL, Katzenellenbogen BS. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol 1996; 10:230-42.
17. Brotherick I, Robson CN, Browell DA, Shenfine J, White MD, Cunliffe WJ, et al. Cytokeratin expression in breast cancer: phenotypic changes associated with disease progression. Cytometry 1998; 32:301-8.
18. Woelfle U, Sauter G, Santjer S, Brakenhoff R, Pantel K. Downregulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res 2004; 10:2670-4.
19. Sartorius CA, Harvell DM, Shen T, Horwitz KB. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res 2005; 65:9779-88.
20. Kuang WW, Thompson DA, Hoch RV, Weigel RJ. Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line. Nucleic Acids Res 1998; 26:1116-23.
21. Long X, Gize EA, Nephew K, Bigsby RM. Evidence for estrogenic contamination of the MAPK inhibitor PD98059. Endocrinology 2001; 142:5390-3.
22. Fan M, Nakshatri H, Nephew KP. Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol 2004; 18:2603-15.
23. Fan M, Long X, Bailey JA, Reed CA, Osborne E, Gize EA, et al. The activating enzyme of NEDD8 inhibits steroid receptor function. Mol Endocrinol 2002; 16:315-30.
24. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66:11954-66.
25. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1996; 55:678-84.
26. Jonas BA, Privalsky ML. SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways. J Biol Chem 2004; 279:54676-86.
27. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997; 277:965-8.
28. Peekhaus NT, Chang T, Hayes EC, Wilkinson HA, Mitra SW, Schaeffer JM, Rohrer SP. Distinct effects of the antiestrogen Faslodex on the stability of estrogen receptors-alpha and -beta in the breast cancer cell line MCF-7. J Mol Endocrinol 2004; 32:987-95.
29. Toivola DM, Ku NO, Resurreccion EZ, Nelson DR, Wright TL, Omary MB. Keratin 8 and 18 hyperphosphorylation is a marker of progression of human liver disease. Hepatology 2004; 40:459-66.
30. Omary MB, Baxter GT, Chou CF, Riopel CL, Lin WY, Strulovici B. PKC epsilon-related kinase associates with and phosphorylates cytokeratin 8 and 18. J Cell Biol 1992; 117:583-93.
31. Mahfoudi A, Roulet E, Dauvois S, Parker MG, Wahli W. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Nat Acad Sci USA 1995; 92:4206-10.
32. Wang H, Peters GA, Zeng X, Tang M, Ip W, Khan SA. Yeast two-hybrid system demonstrates that estrogen receptor dimerization is ligand-dependent in vivo. The J BiolChem 1995; 270:23322-9.
33. Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 2007; 13:3198-206.
34. Iwaya K, Ogawa H, Mukai Y, Iwamatsu A, Mukai K. Ubiquitin-immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer. Cancer Sci 2003; 94:864-70.
35. Kramer G, Erdal H, Mertens HJ, Nap M, Mauermann J, Steiner G, et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 2004; 64:1751-6.
36. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19:264-71.
37. Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, et al. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 1996; 2:1879-85. (Pubitemid 26384156)
38. Takei H, Iino Y, Horiguchi J, Kanoh T, Takao Y, Oyama T, et al. Immunohistochemical analysis of cytokeratin #8 as a prognostic factor in invasive breast carcinoma. Anticancer Res 1995; 15:1101-5.
39. Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, et al. Changes in cytoskeletal protein composition indicative of an epithelialmesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res 2005; 11:8006-14.
40. Buhler H, Schaller G. Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo. Mol Cancer Res 2005; 3:365-71.
41. Schutte B, Henfling M, Ramaekers FC. DEDD association with cytokeratin filaments correlates with sensitivity to apoptosis. Apoptosis 2006; 11:1561-72.
42. Shaw LE, Sadler AJ, Pugazhendhi D, Darbre PD. Changes in oestrogen receptor-alpha and -beta during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells. J Steroid Biochem Mol Biol 2006; 99:19-32.
43. Chen B, Gajdos C, Dardes R, Kidwai N, Johnston SR, Dowsett M, et al. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex. Int J Oncol 2005; 27:327-35.